Santero Therapeutics – Strategic-Technological Analysis
30 pages · PDF · 20 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Santero Therapeutics is a Belgian biotech venture emerging from academic research, dedicated to solving one of the world’s most pressing health security challenges: antibiotic resistance.
Founded in 2021 as a spin-off from the Université Libre de Bruxelles, Santero is pioneering a new class of antibiotics to combat multidrug-resistant “superbugs” that evade existing treatments . At a time when Europe is striving for greater strategic autonomy in critical technologies, Santero’s work targets a vulnerability with both public health and security implications.
Key questions this report answers
- How is Santero developing a new class of antibiotics against multidrug-resistant 'superbugs'?
- What is the maturity of this Université Libre de Bruxelles spin-off's (2021) antimicrobial technology?
- Which health-security markets and partners support its work on antibiotic resistance?
- What capability gaps or dependencies affect its role in European critical-technology autonomy?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Santero Therapeutics, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (20 August 2025). You receive a 30-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · Free summary of this report · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →